Navigation Links
PharMEDium Supports Draft Legislation, Efforts to Strengthen Oversight of the Compounding Industry
Date:4/26/2013

WASHINGTON, April 26, 2013 /PRNewswire/ -- PharMEDium is encouraged by the progress made today by the twelve bipartisan Members of the Senate Health, Education, Labor, and Pensions (HELP) Committee toward assuring the highest level of safety possible for patients who receive sterile compounded preparations. The Senate HELP Committee has produced a detailed and thoughtful Bill which goes a long way toward addressing the complicated but crucial question of how to improve regulatory oversight of this vital sector of the pharmacy industry. 

PharMEDium, the nation's leading provider of sterile admixture preparations for hospitals throughout the country, supports the proposed new category of "compounding manufacturer," federal oversight and inspections of these facilities to applicable cGMP standards. While we recognize this is the beginning of a lengthy legislative process, we encourage those in our industry to join us in supporting these efforts to achieve and maintain the highest quality of safety for users of sterile preparations. PharMEDium has long advocated for increased FDA authority and oversight of the sterile compounding process and looks forward to working with the Committee and Members of Congress on the further development and passage of this important legislation.

Who we are: PharMEDium is one of the nation's leading providers of hospital pharmacy-outsourced, sterile admixture services with centers in four states and thousands of acute care hospital customers nationwide. Our qualified personnel and state-of-the-art centers are registered with the FDA, licensed by states as compounding pharmacies and governed by our own rigorous quality standards. We begin the compounding process with sterile FDA-approved drugs from FDA-approved drug manufacturers. It is our mission to be the preeminent provider of choice for hospital customers and to attain the highest degree of integrity in the compounding of sterile preparations.Contact:

Bob Szafranski Bob.Szafranski@edelman.com312-863-9135 (mobile)312-240-2687 (work)


'/>"/>
SOURCE PharMEDium
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
2. PharMEDium Encourages Swift Action to Strengthen Federal Oversight of Advanced Sterile Compounding
3. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
6. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
7. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
8. Ventana Supports World Patient Safety Day, July 25
9. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
10. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
(Date:2/24/2017)... , Feb. 23, 2017  This report analyzes the ... the following Products: Intermediates, Analytical, and ... report include Pharmaceuticals, and Agrochemicals. The report provides separate ... , Europe , and Rest of ... period 2015 through 2022. Also, a six-year historic analysis ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
(Date:2/22/2017)... York, NY (PRWEB) , ... February 22, 2017 ... ... professional life and athletics. It’s enough to overwork even the sharpest brain. , ... that offer peak healthy activity without over clocking the brain. Each capsule contains ...
Breaking Medicine News(10 mins):